PROTO SCRIPT PHARMACEUTICAL CORP Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2017-10-30: Form 8-K; Period of report 2017-10-25; Description 4.01 Changes in Registrant's Certifying Accountant; Details 4.01.
- 2017-10-19: Form 8-K; Period of report 2017-10-05; Description 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review; Details 4.02.
- 2017-02-15: Form 8-K; Period of report 2017-02-07; Description 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; Details 1.01.
- 2016-11-17: Form 8-K; Period of report 2016-06-29; Description 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Details 5.03.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2017-10-30 | 8-K | 2017-10-25 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 (a) On October 25, 2017, Proto Script Pharmaceutical Corp. (the “Company”) dismissed KLJ & Associates, LLP (“KLJ”) as the Company’s principal accountant. | pscr_8k.htm |
| 2017-10-19 | 8-K | 2017-10-05 | 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review | 4.02 On October 4, 2017, Proto Script Pharmaceutical Corp. (the “Company”) was notified from its registered public accounting firm (the “Auditor”) that the Auditor had provided the Company with consent to file the Company’s Form 10-K for the fiscal year ended December 31, 2016 which the Company previously filed with the Commission on September 20, 2017, prior to receiving final consent to file by the Auditor’s EQR Partner. | pscr_8k.htm |
| 2017-02-15 | 8-K | 2017-02-07 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 3.02 Unregistered Sales of Equity Securities. | f8k021517_8k.htm |
| 2016-11-17 | 8-K | 2016-06-29 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.03 The Board of Directors of Proto Script Pharmaceutical Corp. (the “Company”) resolved that in connection with the closing of the Share Exchange, on June 29, 2016, with Proto-Script Pharmaceuticals Corp., a California Corporation (“PCPC”), the Company has changed its fiscal year end to December 31. | f8k111716_8k.htm |
| 2016-11-07 | 8-K/A | 2016-06-29 | 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 3.02 Unregistered Sales of Equity Securities; 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.06 Change in Shell Company Status | 1.01 On June 29, 2016, the Company entered into a Share Exchange Agreement (the “Share Exchange”) with Proto-Script Pharmaceuticals, Corp., a California corporation (“PSPC”), whereby the Company acquired 100% of the issued and outstanding common stock of PSPC, in exchange for Thirty Million (30,000,000) restricted shares of the Company’s common stock. 2.01 The information provided in Item 1.01 of this Current Report on Form 8-K related to the aforementioned Share Exchange is incorporated by reference into this Item 2.01. 3.02 UNREGISTERED SALES OF EQUITY SECURITIES. 5.01 On June 29, 2016, Michelle Rico acquired control of Thirty Million (30,000,000) shares (the “Exchange Shares”) of the Company’s issued and outstanding common stock, representing approximately 90.77% of the Company’s total issued and outstanding common stock, pursuant to the Share Exchange. 5.02 Mr. Leonardo Correa Rodriguez resigned from all positions with the Company effective as of June 29, 2016, including Director, President, Chief Executive Officer, Chief Financial Officer, Secretary, and Treasurer. 5.06 As a result of execution of the Share Exchange, the Company, although not previously deemed a “shell corporation” as that term is defined in Rule 405 of the Securities Act and Rule 12b-2 of the Exchange Act, is providing the following information to the public to provide full and adequate disclosure regarding the new business direction of the Company and to provide such current adequate information as we believe the public would need in order to make an informed investment decision. | f8ka2102816_8kz.htm |
| 2016-10-14 | 8-K | 2016-10-10 | 8.01 Other Events | 8.01 On October 10, 2016, Yanex Group, Inc. (the “Company”) received approval from FINRA for its previously announced 10 for 1 forward split and name change to Proto Script Pharmaceutical Corp. The name change/forward split took effect at the open of business on October 13, 2016. | f8k101316_8k.htm |
| 2016-10-06 | 8-K | 2016-09-27 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 8.01 Other Events | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. 8.01 On October 4, 2016, Yanex Group, Inc. (the “Company”) filed to change its name to Proto Script Pharmaceutical Corp. The name change will be effected through a parent/subsidiary short-form merger of the Company and its wholly-owned subsidiary, Proto Script Pharmaceutical Corp., a Nevada (the “Subsidiary”), under Section 92A.180 of the Nevada Revised Statutes (“NRS”). | f8k100516_8k.htm |
| 2016-09-22 | 8-K | 2016-09-14 | 3.03 Material Modification to Rights of Security Holders | 3.03 On September 14, 2016, Yanex Group, Inc. (the “Company”) filed a Certificate of Designation of Series A Preferred Stock (the "Certificate of Designation”) with the Nevada Secretary of State designating 10,000,000 of the Company's previously authorized preferred stock. | f8k092016_8k.htm |
| 2016-09-09 | 8-K/A | 2016-06-29 | 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 3.02 Unregistered Sales of Equity Securities; 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.06 Change in Shell Company Status | 1.01 On June 29, 2016, the Company entered into a Share Exchange Agreement (the “Share Exchange”) with Proto-Script Pharmaceuticals, Corp., a California corporation (“PSPC”), whereby the Company acquired 100% of the issued and outstanding common stock of PSPC, in exchange for Thirty Million (30,000,000) restricted shares of the Company’s common stock. 2.01 The information provided in Item 1.01 of this Current Report on Form 8-K related to the aforementioned Share Exchange is incorporated by reference into this Item 2.01. 3.02 UNREGISTERED SALES OF EQUITY SECURITIES. 5.01 On June 29, 2016, Michelle Rico acquired control of Thirty Million (30,000,000) shares (the “Exchange Shares”) of the Company’s issued and outstanding common stock, representing approximately 90.77% of the Company’s total issued and outstanding common stock, pursuant to the Share Exchange. 5.02 Mr. Leonardo Correa Rodriguez resigned from all positions with the Company effective as of June 29, 2016, including Director, President, Chief Executive Officer, Chief Financial Officer, Secretary, and Treasurer. 5.06 As a result of execution of the Share Exchange, the Company, although not previously deemed a “shell corporation” as that term is defined in Rule 405 of the Securities Act and Rule 12b-2 of the Exchange Act, is providing the following information to the public to provide full and adequate disclosure regarding the new business direction of the Company and to provide such current adequate information as we believe the public would need in order to make an informed investment decision. | f8ka090816_8kz.htm |
| 2016-07-05 | 8-K | 2016-06-29 | 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 3.02 Unregistered Sales of Equity Securities; 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.06 Change in Shell Company Status | 1.01 On June 29, 2016, the Company entered into a Share Exchange Agreement (the “Share Exchange”) with Proto-Script Pharmaceuticals, Corp., a California corporation (“PSPC”), whereby the Company acquired 100% of the issued and outstanding common stock of PSPC, in exchange for Thirty Million (30,000,000) restricted shares of the Company’s common stock. 2.01 The information provided in Item 1.01 of this Current Report on Form 8-K related to the aforementioned Share Exchange is incorporated by reference into this Item 2.01. 3.02 UNREGISTERED SALES OF EQUITY SECURITIES. 5.01 On June 29, 2016, Michelle Rico acquired control of Thirty Million (30,000,000) shares (the “Exchange Shares”) of the Company’s issued and outstanding common stock, representing approximately 90.77% of the Company’s total issued and outstanding common stock, pursuant to the Share Exchange. 5.02 Mr. Leonardo Correa Rodriguez resigned from all positions with the Company effective as of June 29, 2016, including Director, President, Chief Executive Officer, Chief Financial Officer, Secretary, and Treasurer. 5.06 As a result of execution of the Share Exchange, the Company, although not previously deemed a “shell corporation” as that term is defined in Rule 405 of the Securities Act and Rule 12b-2 of the Exchange Act, is providing the following information to the public to provide full and adequate disclosure regarding the new business direction of the Company and to provide such current adequate information as we believe the public would need in order to make an informed investment decision. | f8k063016_8k.htm |
| 2016-06-17 | 8-K | 2016-06-16 | 8.01 Other Events | 8.01 Effective June 16, 2016, Yanex Group, Inc. (the “Company”) has changed its corporate address to 9830 6th Street, Suite 103, Rancho Cucamonga, CA, 91730. | f8k061716_8k.htm |
| 2015-10-09 | 8-K | 2015-10-08 | 1.01 Entry into a Material Definitive Agreement; 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 1.01 On October 7, 2015, 2470992 Ontario, Inc. and 2470993 Ontario, Inc. (the “Sellers”) and Leonardo Correa Rodriguez (the “Buyer”) and entered into a stock purchase agreement (the “Stock Purchase Agreement”), whereby the Buyer purchased from the Sellers, Two Million Five Hundred Seventy Eight Thousand (2,578,000) shares of common stock, par value $0.001 per share, of Yanex Group, Inc. (the “Company”), representing approximately 84.58% of the issued and outstanding shares of the Company (the “Shares”), for an aggregate purchase price of $20,000. 5.01 The information provided in Item 1.01 of this Current Report on Form 8-K related to the aforementioned Stock Purchase Agreement is incorporated by reference into this Item 5.01. 5.02 Effective October 7, 2015, Mr. Jason Abbott (“Mr. Abbott”) resigned as the Company’s President, Chief Executive Officer, Chief Financial Officer, Secretary, Treasurer, and Director of the Company. 8.01 Effective October 7, 2015, the Company changed its corporate address to 18881 Von Karman Ave. | form8k.htm |
| 2015-07-16 | 8-K | 2015-07-15 | 1.01 Entry into a Material Definitive Agreement; 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 1.01 On July 15, 2015, Leonardo Correa Rodriguez, our sole officer and director (the “Seller”) and 2470992 Ontario, Inc. and 2470993 Ontario, Inc. (the “Purchasers”) entered into a stock purchase agreement (the “Stock Purchase Agreement”), whereby the Purchaser purchased from the Seller, Two Million Five Hundred Seventy Eight Thousand (2,578,000) shares of common stock, par value $0.001 per share, of Yanex Group, Inc. (the “Company”), representing approximately 84.58% of the issued and outstanding shares of the Company (the “Shares”), for an aggregate purchase price of Twenty Five Thousand Dollars ($25,000) (the “Purchase Price”) paid by the Purchasers through the payment of certain outstanding expenses on behalf of the Company in the amount of the Purchase Price. 5.01 The information provided in Item 1.01 of this Current Report on Form 8-K related to the aforementioned Stock Purchase Agreement is incorporated by reference into this Item 5.01. 5.02 Effective July 15, 2015, Leonardo Correa Rodriguez (“Mr. Rodriguez”) resigned from his positions as the current President, Chief Executive Officer, Chief Financial Officer, Secretary, Treasurer and Director of the Company. 8.01 Effective July 15, 2015, the Company changed its corporate address to 302 Town Centre Boulevard, Suite 100, Markham, Ontario, L3R 0E8, Canada. | form8k.htm |
| 2014-10-08 | 8-K | 2014-08-04 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 (a) On August 4, 2014, Silberstein Ungar, PLLC (“Silberstein”), the principal accountant for Yanex Group, Inc. (the "Company") resigned as the Company’s principal accountant. | form8k.htm |
| 2014-08-15 | 8-K | 2014-07-03 | 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.01 On July 3, 2014, a change in control of Yanex Group, Inc. (the "Company") occurred when Zouk Ventures Ltd. (“Zouk”) sold all of its 2,578,000 common shares in a private share purchase transaction to Kilo Holdings Ltd. (“Kilo”). 5.02 On July 24, 2014, the majority shareholder of the Company voted to remove its sole officer and director Gustavo G. Sune from all of his positions with the Company, including President, CEO, Principal Executive Officer, Treasurer, CFO, Principal Accounting Officer, Secretary, Treasurer and as Director. | form8k.htm |
| 2012-06-01 | 8-K | 2012-05-28 | 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.01 On May 28, 2012, a change in control of Yanex Group, Inc. (the "Company") occurred when Alexander Yanov sold all of his 2,500,000 common shares in a private share purchase transaction to Zouk Ventures Ltd. (“Zouk”). 5.02 On May 28, 2012, the Company received a resignation notice from Alexander Yanov from all of his positions with the Company, including President, CEO, Principal Executive Officer, Treasurer, CFO, Principal Accounting Officer, Secretary, Treasurer and as Director. 8.01 Effective May 28, 2012, the Company has moved its executive offices to Hooft Graaflandstraat 21, 3525 VM Utrecht, Netherland. | f8k.htm |